Related Experiment Video

Updated: May 17, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression

Sven Rottenberg, Jos Jonkers

    Breast Cancer Research : BCR
    |November 7, 2012
    PubMed

    Insights

    Low DUSP4 expression in residual breast cancer activates RAS-ERK signaling, hindering chemotherapy eradication. MEK inhibitors may re-sensitize tumors to docetaxel, offering a new therapeutic strategy for refractory breast cancer.

    Area of Science:

    • Oncology
    • Cancer Biology
    • Pharmacology

    Background:

    • Chemotherapy often fails to eradicate disseminated breast cancer, leading to relapse and drug resistance.
    • Mechanisms behind treatment failure and drug resistance in breast cancer remain poorly understood.
    • Residual tumor cells after treatment pose a significant challenge to achieving a cure.

    Purpose of the Study:

    • To investigate the role of DUSP4 expression in chemotherapy-resistant breast cancer.
    • To explore the activation of RAS-ERK signaling in residual breast cancer cells.
    • To determine if targeting MEK can overcome docetaxel resistance.

    Main Methods:

    • Analysis of DUSP4 expression in residual breast cancer.
    • Assessment of RAS-ERK signaling pathway activation.
    • Evaluation of MEK inhibition in combination with docetaxel using a xenograft model.

    Main Results:

    • Low DUSP4 expression was found to activate RAS-ERK signaling in residual breast cancer.
    • MEK inhibition demonstrated increased sensitivity to docetaxel in a preclinical xenograft model.
    • This suggests a potential therapeutic vulnerability in chemotherapy-refractory breast cancer.

    Conclusions:

    • Low DUSP4 expression is linked to activated RAS-ERK signaling, contributing to chemotherapy resistance in breast cancer.
    • Targeting the MEK pathway presents a promising strategy to enhance docetaxel efficacy against residual and resistant breast cancer.
    • Further research into DUSP4 and RAS-ERK signaling could lead to novel curative strategies for advanced breast cancer.

    More Related Videos

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

    Published on: January 18, 2017

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...